Zhang Xiaoyi, Wu Mian, Peng Gongling, Li Wenhuan, Guo Zhe, Li Hai, Jiang Ming
Department of Thyroid and Breast Surgery, Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China.
Oncol Lett. 2022 Jun 14;24(2):256. doi: 10.3892/ol.2022.13376. eCollection 2022 Aug.
Kinesin family member 2A (KIF2A) has been reported as an oncogene and potential biomarker for the progression of numerous cancer types; however, its role in papillary thyroid carcinoma (PTC) has remained elusive. The present study aimed to assess KIF2A expression in patients with PTC and explore the potential association between KIF2A, clinicopathological features and the prognosis of PTC. A total of 200 patients with PTC who received surgical resection were retrospectively reviewed. KIF2A expression was detected using immunohistochemistry (IHC) in 200 pairs of carcinoma/para-carcinoma tissues and using reverse transcription-quantitative PCR in 91 pairs of carcinoma/para-carcinoma tissues. Clinical and pathological data, disease-free survival (DFS) and overall survival (OS) rates of all patients were obtained. The results of the present study demonstrated that KIF2A protein and mRNA expression were both elevated in carcinoma tissues compared with those in para-carcinoma tissues. KIF2A protein expression in carcinoma tissues was positively associated with increased tumor size and a higher pathologic tumor-nodes-metastasis (pTNM) stage. However, KIF2A mRNA expression in carcinoma tissues was only associated with an increased pTNM stage and not with any other clinicopathological features. In addition, high levels of KIF2A protein expression in carcinoma tissues led to a poor predicted DFS, but were not associated with OS. Following adjustments using a multivariate Cox regression model, high KIF2A protein expression levels were indicated to be independently associated with a decreased DFS. In conclusion, aberrant KIF2A signifies tumor size and invasion, and may help to predict prognosis in patients with PTC.
驱动蛋白家族成员2A（KIF2A）已被报道为多种癌症类型进展的致癌基因和潜在生物标志物；然而，其在甲状腺乳头状癌（PTC）中的作用仍不清楚。本研究旨在评估KIF2A在PTC患者中的表达，并探讨KIF2A、临床病理特征与PTC预后之间的潜在关联。回顾性分析了200例行手术切除的PTC患者。采用免疫组织化学（IHC）检测200对癌组织/癌旁组织中的KIF2A表达，并采用逆转录定量PCR检测91对癌组织/癌旁组织中的KIF2A表达。获取了所有患者的临床和病理数据、无病生存期（DFS）和总生存期（OS）率。本研究结果表明，与癌旁组织相比，癌组织中KIF2A蛋白和mRNA表达均升高。癌组织中KIF2A蛋白表达与肿瘤大小增加和更高的病理肿瘤-淋巴结-转移（pTNM）分期呈正相关。然而，癌组织中KIF2A mRNA表达仅与pTNM分期增加相关，与其他任何临床病理特征均无关。此外，癌组织中高水平的KIF2A蛋白表达导致预测的DFS较差，但与OS无关。经多变量Cox回归模型校正后，高KIF2A蛋白表达水平与DFS降低独立相关。总之，KIF2A异常表明肿瘤大小和侵袭情况，可能有助于预测PTC患者的预后。
